CEBPZ and acute myeloid leukemia: AMLs with translocation involving core-binding factors (CBF) including t(8;21)(q22;q22) and inv(16)(p13;q22) or t(16;16)(p13;q22) constitute a distinct clinicopathologic subtype as defined by the World Health Organization (WHO), and occur in 15–20% of adult patients.1, 2 In general, CBF-AML has a superior outcome compared with other cytogenetic subtypes, with a long-term overall survival (OS) of 40–60%.3, 4, 5, 6, 7 However, their clinical outcome is highly heterogeneous.